- Home
- CAAP vs CNTA Comparison
CAAP vs CNTA Comparison
Compare CAAP & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAAP | CNTA |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | Luxembourg | United Kingdom |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CAAP | CNTA |
|---|---|---|
| Price | $28.95 | $23.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $26.73 | ★ $38.50 |
| AVG Volume (30 Days) | 253.0K | ★ 1.6M |
| Earning Date | 03-18-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $1,872,934,000.00 | $15,000,000.00 |
| Revenue This Year | $5.41 | N/A |
| Revenue Next Year | $7.46 | N/A |
| P/E Ratio | $26.50 | ★ N/A |
| Revenue Growth | 25.19 | ★ 118.88 |
| 52 Week Low | $15.01 | $9.60 |
| 52 Week High | $30.50 | $30.58 |
Technical Indicators
Market Signals| Indicator | CAAP | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 59.41 | 43.38 |
| Support Level | $27.85 | $23.41 |
| Resistance Level | $29.86 | $26.51 |
| Average True Range (ATR) | 1.06 | 1.42 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 68.90 | 40.16 |
Price Performance
Historical ComparisonAbout CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.